Articles tagged with Amyotrophic Lateral Sclerosis
A retrospective study found that multidisciplinary care for ALS significantly decreases multiple emergency hospitalizations and improves survival rates. The study compared patients with ALS treated at a multidisciplinary clinic versus a traditional General Neurology Clinic and showed improved outcomes.
Researchers have discovered a way to predict the course of ALS by measuring immune cells in cerebrospinal fluid. A high proportion of effector T cells is associated with low survival rates, while activated regulatory T cells indicate a protective role against rapid disease progression.
Scientists at UF Scripps Biomedical Research have developed a potential medicine for ALS and dementia by eliminating disease-causing RNA segments. The compound restored neuron health in lab experiments and rescued mice with the disease.
A new hallmark of ALS has been identified, revealing that loss of the RNA processing protein SFPQ leads to motor neuron degeneration. Defective mRNAs accumulate in axons and interfere with normal function, pointing to a possible new target for therapy.
A team from California Institute of Technology has developed a brain-machine interface device that can predict internal speech in patients with tetraplegia. The device, trained on single neurons in the supramarginal gyrus, achieved accuracy up to 91% in predicting eight words.
A collaborative study reveals how genes controlling blood vessel cells influence motor neuron development, allowing them to navigate the body's systems. The discovery sheds light on diseases such as ALS and SMA, where motor neuron connections are destroyed.
Researchers identified a kinase molecule that directs microglia activity, potentially treating neurodegenerative diseases like Alzheimer's and MS. The molecule, called spleen tyrosine kinase, targets plaque buildup and debris accumulation in the brain.
A new study aims to diagnose severe neurodegenerative diseases like ALS and FTD with the help of speech tests. AI can analyze subtle nuances of speech patterns, including pauses, speed, and melodic aspects, to detect early changes.
A small test group has shown that using a patient's own cells in combination with regulatory T-lymphocyte and IL-2 treatment can safely and effectively slow or halt the progression of amyotrophic lateral sclerosis (ALS). This treatment approach was found to be tolerable and biologically active over a period of one year.
Researchers at USF Health successfully tested a protein that activates a unique pathway in cells to increase survival and protect endothelial cells from toxic substances. The study reveals the potential of apolipoprotein A1 as a novel therapeutic for ALS patients, with the goal of slowing disease progression and alleviating symptoms.
Research has found that former Scottish international rugby union players are at a significantly increased risk of developing neurodegenerative diseases, including dementia and motor neurone disease. The study's findings suggest that strategies to reduce head impact and traumatic brain injury in all sports are necessary.
Researchers have identified a new marker for predicting the clinical outcome of patients with Amyotrophic Lateral Sclerosis (ALS) by analyzing brain flexibility during rest. The study found that brains with more flexible functional repertoires tend to have better clinical outcomes.
A new study found that arbitrary age limits and rules on genetic testing for amyotrophic lateral sclerosis (ALS) could be missed, leading to thousands of potential cases going undetected. The researchers argue that genetic testing should be open to all patients with ALS, regardless of age or family history.
A phase 3 clinical trial showed tofersen reduces SOD1 and neurofilament light protein levels, slowing down disease progression. Longer-term use may help stabilize muscle strength and control in people with genetic ALS.
The Critical Path Institute (C-Path) has established a public-private partnership with the FDA and NIH to advance treatments for rare neurodegenerative diseases. The partnership will leverage C-Path's expertise in data management, quantitative analytics, and regulatory science to accelerate medical product development.
A team of researchers has designed in silico molecular probes to track the progress of a misbehaving protein linked to neurodegenerative diseases like ALS and FTD. The probes can detect TDP-43 aggregates at high resolution, paving the way for early diagnosis.
A novel stem cell-gene therapy has been shown to be safe in humans, with no serious side effects reported in the first trial. The treatment targets motor neurons that die in patients with amyotrophic lateral sclerosis (ALS), a fatal neurological disorder.
A team of researchers from Ritsumeikan University in Japan has elucidated the mechanism behind the liquid-solid phase transition of FUS protein that leads to ALS. They discovered a new therapeutic target, arginine, which suppresses FUS aggregation and could delay ALS progression.
A study investigated the frequency and characteristics of non-motor symptoms in ALS patients, finding over 90% experienced symptoms such as fatigue, pain, and sleep disorders. These symptoms reduced QoL even when motor symptoms were mild, highlighting their importance to consider.
A new study finds that the drug terazosin has shown protective effects on motor neurons in models of motor neuron disease (MND), including zebrafish, mice and stem cell models. Researchers hope to launch a full clinical trial if the drug proves successful in a feasibility study involving 50 patients.
A team of researchers has discovered a protein called NOVA1 that displays pathological characteristics in ALS patients at an early stage. This finding could lead to the development of new therapy concepts and potentially enable early detection of the disease.
Researchers found altered cell-mediated immune function in ALS patients and a novel treatment approach using bone marrow transplants. The study suggests that abnormal CD8 T-cell response contributes to motor neuron degeneration.
Researchers from Mount Sinai found a significant connection between the immune system and amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease. The study analyzed mice and human samples using state-of-the-art technologies, revealing peculiar immune signatures that distinguish different forms of ALS.
A new muscle biopsy test could lead to an earlier diagnosis of amyotrophic lateral sclerosis (ALS), a progressive disease affecting nerve cells in the brain and spinal cord. The test targets transactive response DNA-binding protein 43 (TDP-43) accumulation, which may be a biomarker for early ALS diagnosis.
The JNM Molecular Imaging of Neurodegeneration Supplement provides an overview of molecular imaging techniques in neurodegenerative disorders. The supplement aims to improve early and differential diagnosis, as well as stratify and monitor therapy in these disorders.
Research reveals pridopidine enhances autophagy in ALS model, reducing toxic protein aggregation and promoting neuronal health. The study supports pridopidine's potential as a treatment for neurodegenerative diseases like Huntington's disease and Alzheimer's.
Research on experimental drug NU-9 invents by Northwestern University scientists reveals it is more effective than existing FDA-approved drugs for ALS treatment. NU-9 also repairs the axons of diseased upper motor neurons in ALS mouse model, offering a potential new approach to treating the devastating disease.
The Silence ALS program aims to treat patients with rare genetic forms of ALS using antisense oligonucleotides, potentially delaying disease onset or slowing progression. The initiative focuses on individuals identified through Columbia University's ALS Families Project.
Researchers have found a possible target for ALS treatment in astrocyte abnormalities. Astrocytes, a subtype of cells in the central nervous system, are involved in motor neuron death, leading to muscle weakness and paralysis. The study offers hope for developing new drugs to block this process.
A new brain-computer interface device has been found safe in a small study of people with ALS, allowing participants to communicate through text and perform daily tasks. Researchers have also developed a machine-learning decoder that enables independent computer control without eye tracking.
A new study aims to slow muscle degeneration in ALS patients by targeting the renin-angiotensin system. Researchers have found that an investigational drug, CAP-1902, reduces inflammation and oxidative stress in models of Duchenne muscular dystrophy.
Researchers have identified a biomarker, TDP-43, detectable in small skin samples of patients with Amyotrophic Lateral Sclerosis (ALS), allowing for potentially easier diagnosis and early detection. The presence of this protein in the skin of ALS patients is associated with an increased number of fibroblasts with disease marks.
The Hybrid Assistive Limb (HAL) robot has been shown to improve gait ability in patients with amyotrophic lateral sclerosis (ALS), allowing them to walk longer distances with reduced assistance. The therapy sessions, lasting only 20-40 minutes per day for four weeks, also demonstrated preservation of other vital functions.
A study published in eLife found that measuring changes in immune cell populations may help predict the prognosis of patients with ALS. Certain immune cells were associated with better or worse survival rates, providing new insights into the disease's progression.
Researchers discovered that an inorganic polyphosphate released by nerve cells contributes to the death of motor neurons in people with ALS and frontotemporal dementia. The study found that lowering levels of this toxin may be an innovative therapeutic strategy for diverse types of ALS/FTD.
Scientists successfully revive motor neurons in laboratory experiments, showing promise for ALS treatment. The method uses magnetic field pulses to improve nerve function and transport, with healthy cells remaining unchanged.
The Precision ALS programme aims to provide new insights into Motor Neuron Disease through advanced data-driven prediction models and next-generation data analysis. The project will harness AI to analyse large amounts of data from a multimodal dataset, providing tools for clinical trials based on precision-medicine.
Researchers found that mislocalization of TDP-43 protein alters genetic instructions for UNC13A, providing a possible therapeutic target for treating ALS and FTD. The studies suggest that increasing UNC13A or stathmin 2 levels may prevent neuron death in these diseases.
Researchers discover a genetic mechanism linking ALS and dementia to UNC13A protein corruption, providing hope for new treatments by blocking corrupted instructions. The study found that genetic variants increase the risk of UNC13A mRNA corruption in patients with ALS and FTD.
The ALS Canada Research Program has awarded nine Discovery Grants to investigate critical areas of disease processes and clinical care. The grants will support fundamental laboratory research, biomarker studies, and clinical trials.
A new cloud-based data resource has been developed to help identify new subtypes of amyotrophic lateral sclerosis (ALS), a fatal neurological disorder. The tool, part of the Answer ALS collaborative effort, uses biological and clinical data from over 1,000 patients to better understand the disease.
Researchers at University of Gothenburg and Umeå University discovered a link between blood levels of neurofilaments and ALS diagnosis. Blood tests can differentiate ALS from other diseases, offering new opportunities for screening and measuring neurofilaments.
A new meta-analysis of available literature on ALS disease has identified a group of seven environmental chemicals as correlates with increased risk of developing ALS. Exposure to these chemicals, including BMAA and heavy metals, may be contributing to the disease burden in certain regions.
Researchers developed an experimental drug that silences a faulty FUS gene, potentially treating rare and aggressive forms of ALS. The treatment delayed motor neuron degeneration in mice and showed promise in a patient with FUS-ALS.
Researchers found that astrocytes become pro-inflammatory and lose protective functions in ALS, leading to toxic build-up of glutamate that damages motor neurons. The study also identified distinct molecular patterns in astrocytes associated with different ALS-causing genetic mutations.
A UMass Chan clinical trial demonstrates the safety and efficacy of an antisense oligonucleotide in suppressing mutant C9ORF72, a common cause of familial ALS. The treatment led to reduced levels of neurotoxins and stable or improved ALS functional scores.
Researchers have identified a new molecular component of Amyotrophic Lateral Sclerosis (ALS) pathological aggregates, a circular RNA called circ-Hdgfrp3. This circular RNA plays a crucial role in the formation and progression of ALS, highlighting its potential as a therapeutic target.
A study of 19,000 NFL players found a significantly higher incidence of ALS diagnosis and death among players compared to the U.S. male population.
Researchers have determined the molecular structure of TDP-43 aggregates extracted from human brains, shedding light on its role in neurodegenerative diseases like ALS. The discovery may lead to the development of targeted therapies and diagnostic tests.
A new Northwestern study reveals that brain motor neurons degenerate early in diseases like ALS, sending warning signals and showing defects. Targeting the brain's motor neurons could lead to long-term and effective treatment strategies.
A study published in Molecular Genetics and Metabolism found that riluzole slows the progression of Niemann-Pick disease type C1 by reducing glutamate toxicity, increasing mouse survival by 12%. Researchers believe similar drugs may help slow disease progression in patients with NPC1.
Researchers at Universidad Complutense de Madrid have discovered alterations caused by ALS in the retina, which can be used as biomarkers for diagnosis and treatment monitoring. The study found changes in microglial cells and ganglion cell loss, with modifications evolving over the course of the disease.
A study published in Brain Pathology found elevated levels of tau protein in the brains of people with ALS who carry a mutation in the C9orf72 gene. The researchers also identified new genetic mutations in the tau gene and discovered that the ratio of different forms of tau protein may be an indicator of disease progression.
Researchers at Massachusetts General Hospital discovered that reducing abnormal tau can reverse mitochondrial dysfunction and oxidative stress in ALS. By targeting tau with a specific degrader, the study suggests a promising new treatment strategy for this degenerative disease.
A collaboration led by Scripps Research Institute successfully treated C9 ALS/FTD in mice using a novel RNA-hunting compound that recruits the cell's own virus fighter. The compound eliminated 70% of toxic protein fragments and removed most hallmarks of the disease from patient-derived nerve cells.
A new study suggests that vigorous exercise during leisure time is not associated with an increased risk of developing amyotrophic lateral sclerosis (ALS). However, intense physical activity at work hours was linked to a higher risk, possibly due to repetitive motion or exposure to chemicals. Moderate exercise, even after symptoms begi...
A study published in Cell Metabolism identified a protein called neurturin as crucial for muscle health, improving metabolic rates, motor function and exercise capacity. Mice genetically modified to produce more neurturin had increased resistance to degeneration in neurons associated with ALS.
Researchers at University of Illinois Chicago found a potential direct connection between neurodegenerative diseases, such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), glaucoma, and herpesvirus. The study suggests OPTN protein restricts HSV-1 virus spread in cells.
A large epidemiology study found associations between higher HDL and apoA1 levels with a lower risk of ALS. Lower LDL and apoB levels were also linked to decreased risk. These findings may support population screening and preventative therapy for ALS.
A new study from Salk Institute researchers found that a critical threshold of miR-218 levels determines the development of ALS in animal models. The study sheds light on the complex control of gene expression and its implications for treating neurological disorders.